Table 1 Clinical and demographic data of patients with and without post-operative rim-restriction on diffusion-weighted imaging, including the entire study population (n = 272), low-grade glioma subgroup (n = 63) and high-grade glioma subgroup (n = 209).
From: Clinical and prognostic implications of rim restriction following glioma surgery
Entire study population (n = 272) | Low-grade glioma (n = 63) | Glioblastoma (n = 209) | |||||||
|---|---|---|---|---|---|---|---|---|---|
No restriction, n = 204 (74%) | Restriction, n = 68 (26%) | Sig | No restriction, n = 43 (68%) | Restriction, n = 20 (32%) | Sig | No restriction, N = 161 (77%) | Restriction, N = 48 (23%) | Sig | |
Age | 53 ± 17 | 53 ± 15 | 0.734 | 36 ± 11 | 41 ± 13 | 0.152 | 58 ± 15 | 58 ± 13 | 0.824 |
Sex (female, %) | 77 (38%) | 25 (37%) | 0.885 | 27 (63%) | 13 (65%) | 1.0 | 61 (38%) | 18 (38%) | 0.961 |
BMI (kg/m2) | 26.3 ± 4.0 | 26.1 ± 4.3 | 0.657 | 24.9 ± 4.2 | 25.1 ± 4.6 | 0.930 | 26.7 ± 3.9 | 26.5 ± 4.0 | 0.819 |
Pre-op KPS ≥ 70, % | 179 (88%) | 59 (87%) | 0.758 | 60 (98%) | 21 (100%) | 0.744 | 136 (85%) | 39 (81%) | 0.533 |
Ever smoking, % | 26 (13%) | 11 (16%) | 0.475 | 7 (16%) | 4 (20%) | 0.732 | 19 (12%) | 7 (15%) | 0.608 |
Diabetes mellitus | 25 (12%) | 5 (7%) | 0.264 | 2 (4.7%) | 0 | 0.999 | 23 (14%) | 5 (10%) | 0.490 |
IHD | 14 (7%) | 6 (9%) | 0.592 | 1 (2.3%) | 0 | 0.999 | 13 (8%) | 6 (13%) | 0.349 |
Hypertension | 61 (30%) | 14 (21%) | 0.137 | 2 (5%) | 2 (10%) | 0.586 | 57 (35%) | 14 (29%) | 0.423 |
Pre-op serum Hb, g/dL | 13.6 ± 1.7 | 13.5 ± 1.7 | 0.443 | 13.8 ± 1.4 | 13.6 ± 1.3 | 0.617 | 13.6 ± 1.8 | 13.4 ± 1.7 | 0.470 |
Recurrent, % | 72 (35%) | 20 (29%) | 0.375 | 11 (26%) | 5 (25%) | 1.0 | 64 (40%) | 12 (25%) | 0.06 |
Previous radiation, % | 51 (25%) | 11 (16%) | 0.133 | 4 (9%) | 1 (5%) | 0.488 | 49 (30%) | 8 (17%) | 0.06 |
Awake | 73 (36%) | 27 (40%) | 0.561 | 19 (44%) | 11 (55%) | 0.589 | 53 (33%) | 15 (31%) | 0.828 |
Tumor enhancement | 177 (87%) | 57 (84%) | 0.545 | 20 (47%) | 7 (37%) | 0.583 | 160 (99%) | 4 (98%) | 0.361 |
Tumor volume pre-op, cc | 33.3 ± 26.9 | 33.7 ± 28.6 | 0.915 | 35 ± 36 | 33 ± 25 | 0.848 | 32 ± 24 | 36 ± 30 | 0.448 |
Tumor volume post-op, cc | 1.71 ± 3.016 | 2.67 ± 5.712 | 0.186 | 3.36 ± 4.429 | 3.84 ± 3.758 | 0.665 | 1.26 ± 2.34 | 2.19 ± 6.323 | 0.322 |
EOR, % | 94.3 ± 9.2 | 94.2 ± 9.2 | 0.936 | 89 ± 11 | 87 ± 11 | 0.483 | 95.9 ± 7.7 | 96.5 ± 7.4 | 0.672 |
P53 + , % | 87 (55%) | 34 (60%) | 0.550 | 20 (47%) | 12 (60%) | 0.612 | 68 (59%) | 21 (57%) | 0.799 |
IDH 1 + , % | 44 (27%) | 22 (35%) | 0.240 | 28 (65%) | 16 (80%) | 0.377 | 13 (11%) | 9 (21%) | 0.096 |
Frontal | 93 (46%) | 31 (46%) | 0.999 | 18 (42%) | 7 (35%) | 0.783 | 77 (48%) | 22 (46%) | 0.808 |
Insular | 27 (13%) | 5 (7%) | 0.192 | 6 (14%) | 7 (35%) | 0.092 | 14 (9%) | 5 (10%) | 0.716 |
Temporal | 50 (25%) | 25 (37%) | 0.050 | 4 (9%) | 3 (15%) | 0.669 | 46 (29%) | 22 (46%) | 0.025 |
Parietal | 56 (28%) | 18 (27%) | 0.875 | 10 (23%) | 1 (5%) | 0.151 | 51 (32%) | 12 (25%) | 0.376 |
Occipital | 16 (8%) | 6 (9%) | 0.797 | 2 (5%) | 0 | 0.999 | 15 (9%) | 5 (10%) | 0.820 |
